Contrafect Stock News

TYSONS, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery and precision med

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT ) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH ) shares climbed 62.5% to close at $19.50 following its recent listing on NASDAQ. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL ) surged 51.4% to settle at $1.62. Kaival Brands Innovations recently announced the U.S. Court of Appeals for the Eleventh Circuit has granted a judicial stay of the marketing denial order previously issued by the FDA to Bidi Vapor in September 2021. Origin Agritech Limited (NASDAQ: SEED ) gained 34.5% to settle at $6.39 after the company said it expects FY22 sales to exceed RMB150 million. Bakkt Holdings, Inc. (NASDAQ: BKKT ) shares jumped 34% to close at $5.80. Luokung Technology Corp. (NASDAQ: LKCO ) gained 24.3% to close at $0.63. Luokung recently announced the receipt of Nasdaq notification regarding minimum bid price deficiency. Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ) surged 23.2% to settle at $0.8870 after the company announced a research agreement with the University of Pennsylvania evaluating Tc99m tilmanocept as a prognostic marker for glioblastoma.

Photo by freestocks on Unsplash Dr. Roger Pomerantz, Chairman and CEO of ContraFect Corp. (NASDAQ: CFRX ), was a guest speaker at Full story available on Benzinga.com

Aadi Bioscience (NASDAQ:AADI) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Valuation & Earnings This table compares Aadi Bioscience and ContraFects revenue, earnings per share (EPS) and []

Wall Street brokerages expect that ContraFect Co. (NASDAQ:CFRX) will report earnings of ($0.28) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ContraFects earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.30). ContraFect reported earnings of ($0.52) per share []

ContraFect Co. (NASDAQ:CFRX) Analysts at Zacks Investment Research upped their FY2021 earnings estimates for shares of ContraFect in a note issued to investors on Tuesday, November 30th. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will earn ($0.71) per share for the year, up from their previous estimate of ($0.82). []

ContraFect Corporation (NASDAQ:CFRX) concluded the trading at $2.86 on Friday, December 03 with a fall of -9.49% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.16 and 5Y monthly beta was reading 0.97. Considering stocks 52-week price range provides that CFRX ContraFect Corporation (CFRX) Volatility Hits 14.06% : Keep Your Head Up Read More »